Evotec has been granted a patent for ophthalmic formulations containing aflibercept for treating eye disorders. The formulation includes specific concentrations of aflibercept, histidine buffer, non-ionic surfactant, tonicifying agent, amino acid stabilizing agent, and maintains a pH range of 5.0 to 6.5. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Ophthalmic formulation for treating eye disorders with aflibercept
A recently granted patent (Publication Number: US12005097B2) discloses an ophthalmic formulation designed for treating various eye disorders or diseases. The formulation includes aflibercept in a concentration range of 5-100 mg/mL, a histidine buffer at 5-50 mM, a non-ionic surfactant such as polysorbate or Poloxamer, a tonicifying agent like a polyol or amino acid, an additional amino acid stabilizing agent, and maintains a pH range of about 5.0 to 6.5. The formulation's final osmolality is set at 300±50 mOsm/kg, ensuring compatibility with ocular tissues.
Moreover, the patent covers a method for treating eye disorders like macular edema following Retinal Vein Occlusion (RVO), Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO), Neovascular Age-Related Macular Degeneration (AMD), and others. The method involves administering the ophthalmic formulation intravitreally to patients in need of treatment. By specifying the concentrations of key components and the targeted eye conditions, this patent provides a detailed framework for effective treatment strategies in ophthalmology, potentially improving outcomes for patients suffering from a range of ocular ailments.
To know more about GlobalData’s detailed insights on Evotec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
